15. A hybridoma selected from 5F8 (ECACC No.95121524), 2H6 (ECACC No.95121526) and 5D8 (ECACC No.95121527).

16. A monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas according to claim 15.

A DOCPHOENIX

BACKFILE DOCUMENT INDEX SHEET

APPL PARTS

_____ IMIS ____
Internal Misc. Paper

_____ LET. ____
Misc. Incoming Letter

_____ 371P ____
PCT Papers in a 371Application

_____ A... ____
Amendment Including Elections

_____ ABST ____
Abstract

_____ ADS ____
Application Data Sheet

_____ AF/D ____
Affidavit or Exhibit Received

_____ APPENDIX ____
Appendix

_____ ARTIFACT ____
Artifact

_____ BIB ____
Bib Data Sheet

_____ CLM ____
Claim

_____ COMPUTER ____
Computer Program Listing

_____ CRFL ____
All CRF Papers for Backfile

_____ DIST ____
Terminal Disclaimer Filed

_____ DRW ____
Drawings

_____ FOR ____
Foreign Reference

_____ FRPR ____
Foreign Priority Papers

_____ IDS ____
IDS Including 1449

_____ NPL ____
Non-Patent Literature

_____ OATH ____
Oath or Declaration

_____ PET. ____
Petition

_____ RETMAIL ____
Mail Returned by USPS

_____ SEQLIST ____
Sequence Listing

_____ SPEC ____
Specification

_____ SPEC NO ____
Specification Not in English

_____ TRNA ____
Transmittal New Application

OUTGOING

_____ CTMS ____
Misc. Office Action

_____ 1449 ____
Signed 1449

_____ 892 ____
892

_____ ABN ____
Abandonment

_____ APDEC ____
Board of Appeals Decision

_____ APEA ____
Examiner Answer

_____ CTAV ____
Count Advisory Action

_____ CTEQ ____
Count Ex parte Quayle

_____ CTFR ____
Count Final Rejection

_____ CTNF ____
Count Non-Final

_____ CTRS ____
Count Restriction

_____ EXIN ____
Examiner Interview

_____ M903 ____
DO/EO Acceptance

_____ M905 ____
DO/EO Missing Requirement

_____ NFDR ____
Formal Drawing Required

_____ NOA ____
Notice of Allowance

_____ PETDEC ____
Petition Decision

INCOMING

_____ AP.B ____
Appeal Brief

_____ C.AD ____
Change of Address

_____ N/AP ____
Notice of Appeal

_____ PA.. ____
Change in Power of Attorney

_____ REM ____
Applicant Remarks in Amendment

_____ XT/ ____
Extension of Time filed separate

Internal

_____ SRNT ____
Examiner Search Notes

_____ CLMPTO ____
PTO Prepared Complete Claim Set

_____ ECBOX ____
Evidence Copy Box Identification

_____ WCLM ____
Claim Worksheet

_____ WFEE ____
Fee Worksheet

File Wrapper

_____ FWCLM ____
File Wrapper Claim

_____ IIFW ____
File Wrapper Issue Information

_____ SRFW ____
File Wrapper Search Info

1997-08-25

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 7/01, A61K 39/40, C07K 16/12 // 19/00

A1

(11) International Publication Number: WO 97/29185

(43) International Publication Date: 14 August 1997 (14.08.97)

(21) International Application Number: PCT/SE97/00172

(22) International Filing Date: 5 February 1997 (05.02.97)

(30) Priority Data:
9600434-6 6 February 1996 (06.02.96) SE

(71)(72) Applicant and Inventor: MÅRDH, Sven [SE/SE]; Sjöliden 13, S-590 77 Vreta Kloster (SE).

(74) Agent: GÖTEBORGS PATENTBYRÅ AB; P.O. Box 5005, S-402 21 Göteborg (SE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: RECOMBINANT PHAGES

(57) Abstract

The present invention relates to bacteriophages for use in the treatment or prophylaxis of bacterial infections, especially mucosal bacterial infections such as *Helicobacter pylori* infections. In particular, it relates to modified filamentous bacteriophages, e.g. M13 phages, for such use, which bacteriophages present at its surface a recombinant protein comprising: (i) a first component derived from a bacteriophage surface protein; and (ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site, said second component rendering said bacteriophage capable of binding to and thereby inhibiting growth of bacterial cells involved in the etiology of said infection.